Recurrent Ovarian Carcinoma Active Not Recruiting Phase 2 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00886691Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTreatment
NCT02283658Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerTreatment